Research programme: hepatitis C therapeutics - CelgeneAlternative Names: AVL-181; AVL-192
Latest Information Update: 09 Mar 2012
At a glance
- Originator Avila Therapeutics
- Developer Celgene Corporation
- Class Small molecules
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hepatitis C